ESCRS Board Member Prof.Dr. Ewa Mrukwa-Kominek told that Acriva Trinova implanted patients do not experience glare and halos and have very sharp visual equity.
Halos are bright circles that surround a light source, like headlights. Glare is light that enters your eye and interferes with your vision. These vision problems can be very disturbing even disabling after a cataract surgery.
As far as Intraocular lenses are concerned, sharp edges and pointy peaks of the overlapping pattern on the traditional trifocal IOLs are the main causes of halo and glare since they cause unwanted scattering of light.
Acriva Trinova is produced with Sinusoidal Vision Technology (SVT) which is a unique patent pending technique for producing a trifocal IOL surface that does not exhibit any sharp edges. The lens optic has smoothly varying surface profile that helps to reduce halo/glare due to the reduced scattered light.
ESCRS Board Member Prof.Dr. Ewa Mrukwa-Kominek talked about superior features of Acriva Trinova. She says that Acriva Trinova implanted patients do not experience glare and halos and have very sharp visual equity.
To watch the interview of Prof.Dr. Ewa Mrukwa-Kominek, you can click the link below
About VSY Biotechnology
VSY Biotechnology is a progressive and innovative company that focuses on consumer satisfaction by creating superior state-of-the-art ophthalmology and orthopedics products designed and manufactured to greatly enhance and improve vision and comfort for a wide range of patients around the globe. To meet the needs of patients and healthcare professionals around the globe, VSY Biotechnology serves to more than 60 countries around the globe from the headquarter in Amsterdam, The Netherlands.